Preoperative Right Hepatic Artery Embolization to enable surgery for advanced perihilar cholangiocarcinoma
Official title: A Prospective, Multicenter, Single-Arm Study on the Efficacy and Safety of Preoperative Right Hepatic Artery Embolization Combined With Surgical Resection for Locally Advanced Bismuth IIIb and IV Perihilar Cholangiocarcinoma
Run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT07326189 · Data updated 2026-11-12
A single-arm study tests whether embolizing the right hepatic artery before surgery helps patients with unresectable, locally advanced perihilar cholangiocarcinoma become eligible for radical liver surgery.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 33 (estimated) |
| Sponsor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Academic / other |
| Locations | 1 site (Guangzhou, Guangdong) |
| Status | Recruiting |
| Started | April 1, 2026 |
| Main results expected | March 31, 2028 |
| Study ends | March 31, 2029 |
| Registry record updated | November 9, 2026 |
| Trial ID | NCT07326189 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18-80 with Bismuth IIIb or IV perihilar cholangiocarcinoma invading the right hepatic artery and suitable for left-sided liver resection.
✕Probably not a fit
Patients without adequate collateral development or with unresectable disease after embolization may not benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective, multicenter study examines whether selectively embolizing the tumor-involved right hepatic artery can promote collateral blood supply to the liver, allowing radical resection without arterial reconstruction. After embolization, imaging confirms collateral development, and patients undergo left hepatectomy or left trisectionectomy with en-bloc resection of the involved artery. The primary goal is to improve 1-year overall survival compared with historical controls, with secondary goals including conversion to surgery, R0 resection rate, and longer-term survival and safety outcomes.
Why it matters
Potential benefit: If successful, patients may become candidates for curative surgery and experience improved survival.
How similar studies have gone: This approach is novel and exploratory; previous strategies for arterial-embolization-assisted resection have limited data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Signed informed consent. * Age 18-80 years. * Clinical diagnosis of Bismuth IIIb or IV perihilar cholangiocarcinoma, deemed suitable for radical resection via left hepatectomy or left trisectionectomy. * Imaging (CTA/MRA) confirms tumor invasion of the right hepatic artery (RHA) that is assessed as "unable to be safely reconstructed after resection" (e.g., involvement of RHA branches or requiring vascular graft for reconstruction). * Portal vein on the side of the future liver remnant is not invaded or is reconstructable. * ECOG performance status 0-1. * Child-Pugh score ≤ 7 (Class A or B). * Adequate organ function (bone marrow, liver, kidney) as per protocol-defined laboratory values. * Expected survival ≥ 12 weeks. Exclusion Criteria: * Evidence of distant metastasis (M1). * History of other malignancies within the past 5 years (except cured basal cell carcinoma or cervical carcinoma in situ). * Severe cardiac, pulmonary, renal, or cerebrovascular disease as specified in the protocol (e.g., recent myocardial infarction, severe COPD, chronic renal failure stage ≥ III). * Uncontrolled active infection or diabetes. * Pregnancy or lactation. * Allergy to iodinated contrast media. * Postoperative pathology confirms non-cholangiocarcinoma.
Where it's running
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China Recruiting
Study contacts
- Study coordinator: Xiangde Shi, Doctor
- Email: sxdsdgsdg@126.com
- Phone: +86-13826064911
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Investigating liver and pancreas surgery followed by transplantation for advanced cholangiocarcinoma
This study is testing a new surgery method for patients with advanced bile duct cancer to see if removing the liver and pancreas together, followed by a liver transplant, can help them live longer.
-
Combination therapy for patients with unresectable intrahepatic cholangiocarcinoma
This study is testing a new combination of chemotherapy and targeted therapy to see if it can shrink tumors in patients with a type of liver cancer that can't be surgically removed.
-
Combination treatment for advanced bile duct cancer
This study is testing a new combination treatment for patients with advanced bile duct cancer that can't be surgically removed to see if it helps them feel better and live longer.
-
Hepatic arterial infusion of gemcitabine and oxaliplatin for treating non-resectable intra-hepatic cholangiocarcinoma
This study is testing a new way to deliver two cancer drugs directly to the liver to see if it helps patients with a specific type of liver cancer that can't be surgically removed.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.